© 2004 by European Society of Cardiology
Copyright © 2004, European Society of Cardiology
Interference of antihypertrophic molecules and signaling pathways with the Ca2+–calcineurin–NFAT cascade in cardiac myocytes
Department of Cardiology and Angiology, Hannover Medical School, Carl-Neuberg Str. 1, 30625, Hannover, Germany
* Corresponding author. Tel.: +49-511-532-4055; fax: +49-511-532-5412. Email address: wollert.kai{at}mh-hannover.de
Cardiac hypertrophy occurs in a number of disease states associated with chronic increases in cardiac work load. Although cardiac hypertrophy may initially represent an adaptive response of the myocardium, ultimately, it often progresses to ventricular dilatation and heart failure. Much investigation has focused on the signaling pathways controlling cardiac hypertrophy at the level of the single cardiac myocyte. One prohypertrophic pathway that has received much attention involves the ubiquitously expressed Ca2+/calmodulin-activated phosphatase calcineurin. Upon activation by Ca2+, calcineurin dephosphorylates nuclear factor of activated T cell (NFAT) transcription factors, leading to their nuclear translocation. As common in complex biological systems, cardiac hypertrophy is controlled simultaneously by stimulatory (prohypertrophic) and counter-regulatory (antihypertrophic) pathways. Given the potent prohypertrophic effects of the Ca2+–calcineurin–NFAT pathway in cardiac myocytes, it is not surprising that the activity of this pathway is tightly controlled at multiple levels. Inhibitory mechanisms upstream (nitric oxide (NO), cGMP, cGMP-dependent protein kinase type I (PKG I), heme oxygenase-1 (HO-1), biliverdin, carbon monoxide (CO)) and downstream from calcineurin (glycogen synthase kinase-3 (GSK3), c-Jun N-terminal kinases (JNKs), p38 mitogen-activated protein kinase (MAPKs)) have been described. Moreover, several inhibitors directly target calcineurin enzymatic activity (cyclosporine A (CsA), tacrolimus (FK506), calcineurin-binding protein-1 (Cabin-1)/calcineurin-inhibitory protein (Cain), A-kinase-anchoring protein-79 (AKAP79), calcineurin B homology protein (CHP), MCIPs, VIVIT). Considering the dominant role of the calcineurin pathway in cardiac hypertrophy and failure, calcineurin-inhibitory strategies may lead to the identification of novel therapeutic approaches for patients with cardiac disease.
KEYWORDS Hypertrophy; Calcium (cellular); Protein phosphatases; Signal transduction
Time for primary review 17 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Semigran Myocardial effects of PDE5 inhibition: more function with less mass. J. Am. Coll. Cardiol., January 13, 2009; 53(2): 216 - 217. [Full Text] [PDF]
|
|
|
|
 |
|
 B. K. Pedersen and M. A. Febbraio Muscle as an Endocrine Organ: Focus on Muscle-Derived Interleukin-6 Physiol Rev, October 1, 2008; 88(4): 1379 - 1406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. D. Folmes, L. A. Witters, M. F. Allard, M. E. Young, and J. R. B. Dyck The AMPK {gamma}1 R70Q mutant regulates multiple metabolic and growth pathways in neonatal cardiac myocytes Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3456 - H3464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wang, J. L. Pluznick, D. C. Settles, and S. C. Sansom Association of VASP with TRPC4 in PKG-mediated inhibition of the store-operated calcium response in mesangial cells Am J Physiol Renal Physiol, December 1, 2007; 293(6): F1768 - F1776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. A.M. van de Schans, S. W.M. van den Borne, A. E. Strzelecka, B. J.A. Janssen, J. L.J. van der Velden, R. C.J. Langen, A. Wynshaw-Boris, J. F.M. Smits, and W. M. Blankesteijn Interruption of Wnt Signaling Attenuates the Onset of Pressure Overload-Induced Cardiac Hypertrophy Hypertension, March 1, 2007; 49(3): 473 - 480. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wenzel, C. Rohde, S. Wingerning, J. Roth, G. Kojda, and K.-D. Schluter Lack of Endothelial Nitric Oxide Synthase-Derived Nitric Oxide Formation Favors Hypertrophy in Adult Ventricular Cardiomyocytes Hypertension, January 1, 2007; 49(1): 193 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Murdoch, M. Zhang, A. C. Cave, and A. M. Shah NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure Cardiovasc Res, July 15, 2006; 71(2): 208 - 215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-H. Cheng, N.-L. Shih, S.-Y. Chen, J.-W. Lin, Y.-L. Chen, C.-H. Chen, H. Lin, C.-F. Cheng, W.-T. Chiu, D. L. Wang, et al. Nitric Oxide Inhibits Endothelin-1-Induced Cardiomyocyte Hypertrophy through cGMP-mediated Suppression of Extracellular-Signal Regulated Kinase Phosphorylation Mol. Pharmacol., October 1, 2005; 68(4): 1183 - 1192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Pelzer, V. Jazbutyte, K. Hu, S. Segerer, M. Nahrendorf, P. Nordbeck, A. W. Bonz, J. Muck, K.-H. Fritzemeier, C. Hegele-Hartung, et al. The estrogen receptor-{alpha} agonist 16{alpha}-LE2 inhibits cardiac hypertrophy and improves hemodynamic function in estrogen-deficient spontaneously hypertensive rats Cardiovasc Res, September 1, 2005; 67(4): 604 - 612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Burkhoff and S. A. Ben-Haim Nonexcitatory electrical signals for enhancing ventricular contractility: rationale and initial investigations of an experimental treatment for heart failure Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2550 - H2556. [Full Text] [PDF]
|
|
|
|
|
|
A. M. Shah Divergent roles of endothelial nitric oxide synthase in cardiac hypertrophy and chamber dilatation? Cardiovasc Res, June 1, 2005; 66(3): 421 - 422. [Full Text] [PDF]
|
|
|
|
|
|
G. W. Booz Putting the Brakes on Cardiac Hypertrophy: Exploiting the NO-cGMP Counter-Regulatory System Hypertension, March 1, 2005; 45(3): 341 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Heineke, H. Ruetten, C. Willenbockel, S. C. Gross, M. Naguib, A. Schaefer, T. Kempf, D. Hilfiker-Kleiner, P. Caroni, T. Kraft, et al. Attenuation of cardiac remodeling after myocardial infarction by muscle LIM protein-calcineurin signaling at the sarcomeric Z-disc PNAS, February 1, 2005; 102(5): 1655 - 1660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-D. Schluter and K. C Wollert Synchronization and integration of multiple hypertrophic pathways in the heart Cardiovasc Res, August 15, 2004; 63(3): 367 - 372. [Full Text] [PDF]
|
|